COGT
Income statement / Annual
Last year (2025), Cogent Biosciences Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Cogent Biosciences Inc's net income was -$328.94 M.
See Cogent Biosciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$7.87 M |
$22.50 M |
$9.73 M |
$8.36 M |
$6.36 M |
| Cost of Revenue |
$4.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$25.74 M
|
$43.71 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$4.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$17.87 M
|
$22.46 M
|
$9.73 M
|
$8.36 M
|
$6.36 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
-2.27
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$269.78 M
|
$232.66 M
|
$173.76 M
|
$121.63 M
|
$55.91 M
|
$72.65 M
|
$43.71 M
|
$38.29 M
|
$29.83 M
|
$21.99 M
|
| General & Administrative Expenses |
$63.58 M
|
$43.28 M
|
$34.38 M
|
$26.21 M
|
$19.64 M
|
$17.42 M
|
$10.97 M
|
$7.45 M
|
$4.68 M
|
$3.43 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$63.58 M
|
$43.28 M
|
$34.38 M
|
$26.21 M
|
$19.64 M
|
$17.42 M
|
$10.97 M
|
$7.45 M
|
$4.68 M
|
$3.43 M
|
| Other Expenses |
-$4.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$25.74 M
|
$78.00 K
|
$320.00 K
|
$274.00 K
|
$0.00
|
| Operating Expenses |
$328.74 M
|
$275.94 M
|
$208.13 M
|
$147.84 M
|
$75.55 M
|
$64.33 M
|
$54.68 M
|
$45.74 M
|
$34.51 M
|
$25.43 M
|
| Cost And Expenses |
$333.36 M
|
$275.94 M
|
$208.13 M
|
$147.84 M
|
$75.55 M
|
$90.07 M
|
$54.68 M
|
$45.74 M
|
$34.51 M
|
$25.43 M
|
| Interest Income |
$14.69 M
|
$18.09 M
|
$13.08 M
|
$3.99 M
|
$467.00 K
|
$144.00 K
|
$267.00 K
|
$1.15 M
|
$386.00 K
|
$265.00 K
|
| Interest Expense |
$3.06 M
|
$0.00
|
$0.00
|
$3.99 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4.62 M
|
$4.35 M
|
$3.59 M
|
$5.88 M
|
$1.99 M
|
$720.00 K
|
$1.29 M
|
$1.32 M
|
$1.17 M
|
$830.00 K
|
| EBITDA |
-$328.74 M |
-$271.59 M |
-$204.54 M |
-$141.96 M |
-$73.56 M |
-$34.57 M |
-$30.89 M |
-$34.68 M |
-$24.98 M |
-$18.24 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-4.39
|
-1.37
|
-3.56
|
-2.99
|
-2.87
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-10.44
|
-1.43
|
-3.7
|
-3.13
|
-3
|
| Total Other Income/Expenses Net |
$4.43 M
|
$20.08 M
|
$15.72 M
|
$7.60 M
|
$3.28 M
|
$7.39 M
|
$345.00 K
|
$1.47 M
|
$660.00 K
|
$946.00 K
|
| Income Before Tax |
-$328.94 M
|
-$255.86 M
|
-$192.41 M
|
-$140.24 M
|
-$72.27 M
|
-$74.81 M
|
-$31.83 M
|
-$34.53 M
|
-$25.49 M
|
-$18.12 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-9.5
|
-1.41
|
-3.55
|
-3.05
|
-2.85
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$328.94 M
|
-$255.86 M
|
-$192.41 M
|
-$140.24 M
|
-$72.27 M
|
-$74.81 M
|
-$30.27 M
|
-$34.53 M
|
-$25.49 M
|
-$18.12 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-9.5
|
-1.35
|
-3.55
|
-3.05
|
-2.85
|
| EPS |
-2.55 |
-2.46 |
-2.42 |
-2.26 |
-1.85 |
-6 |
-3.97 |
-5.55 |
-3.45 |
-3.1 |
| EPS Diluted |
-2.55 |
-2.46 |
-2.42 |
-2.26 |
-1.85 |
-6 |
-3.97 |
-5.55 |
-3.45 |
-2.45 |
| Weighted Average Shares Out |
$67.60 M
|
$103.86 M
|
$79.66 M
|
$58.74 M
|
$38.73 M
|
$11.08 M
|
$7.62 M
|
$6.22 M
|
$7.40 M
|
$5.86 M
|
| Weighted Average Shares Out Diluted |
$67.60 M
|
$103.86 M
|
$79.66 M
|
$58.74 M
|
$38.73 M
|
$11.08 M
|
$7.62 M
|
$6.22 M
|
$7.40 M
|
$7.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
